September 15, 2023
Don't miss this opportunity to explore the intriguing world of computer-guided drug design as we compare two innovative methodologies: fragment-based drug design and full molecule-based drug design. Our esteemed panelists will delve into these two approaches' strengths, limitations, and future prospects while uncovering potential synergies.
This is an engaging webinar where we unravel the promises and possibilities offered by these cutting-edge approaches.
Featuring these leading scientists...
Barry Bunin, PhD
CEO, Collaborative Drug Discovery
Barry Bunin founded CDD in 2004 to pioneer CDD Vault, a hosted research data management system. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly, as well as the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty).
On the scientific side, Dr. Bunin is an expert in cheminformatics and combinatorial chemistry, and has written two books in those fields. He is also on the patent of Kyprolis, a selective proteasome inhibitor for treating multiple myeloma.
Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.
Eric Martin, PhD
Director, Computational Chemistry at Novartis
Eric Martin has a Ph.D. in physical organic chemistry from Yale University. He has worked in computational drug design and herbicide design for 40 years at Dow, DowElanco, Chiron and Novartis. He is currently developing novel methodologies for two areas of drug discovery: 1) Developing “Profile-QSAR”, a massively multitask machine learning method that builds experimental-quality virtual screening models for over 9000 IC50 assays, and 2) “rational oral bioavailability design” during lead optimization, by applying global sensitivity analysis to physiologically-based pharmacokinetics simulations. Eric was awarded the lifetime title of Novartis Leading Scientist for the former.
Daniel Erlanson, PhD
SVP, Innovation and Discovery at Frontier Medicines
Daniel Erlanson is an expert in fragment-based and covalent drug discovery. Prior to Frontier, Dan co-founded Carmot Therapeutics, where he developed drug discovery technologies and led chemistry efforts that resulted in three clinical-stage molecules and partnerships with biotech companies including Amgen and Genentech. One of the molecules advanced by Amgen is LUMAKRAS™ (sotorasib), the first FDA and EMA approved inhibitor of KRASG12C, a previously undruggable target.
Dr. Erlanson earned his Ph.D. in Chemistry from Harvard University in the laboratory of Gregory L. Verdine.